

Auris Medical

16:06 14 Mar 2018

Auris Medical plunges as its Keyzilen tinnitus treatment fails pivotal late-stage study

Auris Medical Holding AG (NASDAQ:EARS) was the top faller on Wall Street on Monday after the Swiss biopharma's tinnitus treatment candidate failed in a key late-stage study.

Preliminary top-line data from the TACTT3 trial showed patients taking Keyzilen failed to register a "statistically significant improvement" when compared to those taking a placebo.

"The company is investigating the outcomes, including those in the previously conducted sister trial TACTT2, and will provide an update in due course," read a statement late on Tuesday.

Had it have been successful, the in-ear injection could have been the first drug to gain approval for treating acute inner ear tinnitus.

Alongside news of the failure, Auris announced a share consolidation which sees one new share issued to investors for every ten of the old shares.

Allowing for the consolidation, shares were down 38.3% to US\$1.55 shortly after midday on Monday.

Price: US\$0.9

Market Cap: US\$5.51M

1 Year Share Price Graph



Share Information

Code: EARS

Listing: NASDAQ

52 week High Low
9.698p 0.852p

Sector: MSN - Healthcare & pharmaceuticals

Website: www.aurismedical.com

Company Synopsis:

Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. It has two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, it has AM-125 in early clinical development for the treatment of vertigo.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.